DCPH News and Press, Deciphera Pharmaceuticals Inc. From 01/06/20

Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 38 th Annual J.P. Morgan Healthcare Conference on Monda...

Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) lept over 31% last month, according to data from  S&P Global Market Intelligence . The monthly run-up topped 45% at one point before shares cooled off in the final days of the decade. Despite that, the stock erupted for a 196% gain ...

The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...

- Application is Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program - - Positive Results from Company’s INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) Form Basis of Submission - D...

Biotech investors are on the edge of their seats this holiday season thanks to a recent string of juicy buyout offers. Despite a busy year for acquisitions, big pharmaceutical companies with pipelines to fill and money to spend have been jumping over each other to acquire smaller biotechs at ste...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this Read more ...

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...

- Former CEO of Array BioPharma Brings Expertise in Oncology Drug Development and Commercialization - Deciphera Pharmaceuticals, Inc . (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appointed Ro...

Ripretinib is Deciphera's ( DCPH ) lead drug candidate and it is being tested in GIST, or gastrointestinal stromal tumors. Recently, the drug fared positively in a phase 3 trial called INVICTUS evaluating ripretinib in patients with fourth-line and fourth-line plus GIST. Given those result...